The results emphasise benralizumab’s efficacy in inducing a rapid and durable clinical remission in patients with SEA.
Navigating the shift to next-generation propellants in pMDIs by balancing environmental goals, patient care, and regulatory demands.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback